Health In Tech to Announce Third Quarter 2026 Financial Results on November 12, 2026
STUART, Fla., Oct. 29, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT), an AI-enabled InsurTech platform company, today announced that it will release financial results for the third quarter ended September 30, 2026, following the close of...
Paying Subscribers Hit a Record High of 19.83 Million!
Meitu, Inc. （ Stock Code: 1357.HK ） 2026 Investor Day Highlights Focused AI Innovation and Global "Scale-Up" HONG KONG, Oct. 29, 2026 /PRNewswire/ -- Meitu, Inc. (collectively, "Meitu" or "Company" and stock code: 1357.HK), a global leading provider...
G-P Recognized by Inc. for Empowering Businesses to Grow and Succeed Globally
G-P named a 2026 Inc. Power Partner Award Winner in HR & People Operations BOSTON, Oct. 28, 2026 /PRNewswire/ -- G-P (Globalization Partners), the leader in AI-driven global employment, ranked No. 1 by industry analysts, today announced it has...
Master Concept Earns 2026 Cloudflare Growth Partner of the Year Award
HONG KONG, Oct. 28, 2026 /PRNewswire/ -- On October 19, Master Concept announced it has been awarded by Cloudflare, Inc., the leading connectivity cloud company, for Growth Partner of the Year Award. Master Concept Earns 2026 Cloudflare Growth...
New Indication Application for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Accepted for Review by NMPA
This is the seventh indication application for sacituzumab tirumotecan (sac-TMT) and the second application for the ADC plus IO combination regimen of sac-TMT plus pembrolizumab accepted for review. The Phase III OptiTROP-Lung06 study supporting...
111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
SHANGHAI, Oct. 26, 2026 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), comprising three independent...
DiDi Shareholders Overwhelmingly Back Hong Kong Relisting; Want Independent Director, Open Earnings Calls, and First Shareholder Meeting in Four Years, Survey Finds
A Heng Ren Partners survey this month finds at least 99.3% support on five key shareholder issues to boost shareholder value; shareholders want DiDi's board and management to respond with concrete action BOSTON, Oct. 26, 2026 /PRNewswire/ -- Heng...
Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of death (HR 0.69; 95% CI 0.54–0.89; one-sided P = 0.0021). The 2-year OS rate was 54.1% vs 37.2%, an...
The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65; P<0.0001 ), and median PFS was 15.0 months (95% CI 9.9-NE) and 5.7 months (95% CI 5.5-7.4) in the two...
2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC
SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major...